A New Approach for Advanced Pancreatic Cancer? Exploring Surgery and HIPEC
- May 4
- 2 min read
Gudmundsdottir H, Yonkus JA, Thiels CA, Warner SG, Cleary SP, Kendrick ML, Truty MJ, Grotz TE. Oncologic Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Highly Selected Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol. 2023 Nov;30(12):7833-7839. doi: 10.1245/s10434-023-14138-3. Epub 2023 Aug 19. PMID: 37596449.
What is this study about?
This study looked at a challenging situation: pancreatic cancer that has spread to the lining of the abdomen (called peritoneal metastases).
In most cases, when pancreatic cancer spreads this way, treatment is palliative chemotherapy—meaning it is focused on slowing the disease and managing symptoms rather than curing it. Outcomes are often poor, and new approaches are needed.
Researchers wanted to explore whether a more aggressive approach—surgery to remove visible tumors (cytoreductive surgery) followed by HIPEC—might help carefully selected patients live longer.
What is HIPEC?
HIPEC (hyperthermic intraperitoneal chemotherapy) is a treatment where:
Surgeons remove as much visible cancer as possible
Heated chemotherapy is then circulated directly inside the abdomen
The heat helps the chemotherapy work better and reach cancer cells more effectively.
What did researchers do?
The study reviewed patients with pancreatic cancer that had spread to the abdominal lining who underwent:
Cytoreductive surgery (CRS)
Followed by HIPEC treatment
These patients were compared to what is typically expected with standard treatment.
What did they find?
In carefully selected patients, this combined approach may provide a survival benefit
Some patients lived longer than what is usually expected with standard chemotherapy alone
The treatment was feasible, meaning it could be performed safely in specialized centers
However, this benefit was not seen in all patients, and careful selection was very important.
What does this mean for patients?
For most people with pancreatic cancer that has spread to the abdomen:
Standard treatment remains systemic chemotherapy
But this study suggests that:
A small group of patients may benefit from more aggressive treatment
Surgery + HIPEC could be an option in highly selected cases, usually at specialized centers
Why is this important?
Pancreatic cancer with abdominal spread is difficult to treat, and survival rates are typically low. This research offers early evidence that new approaches may improve outcomes for some patients, which is an important step forward.
What are the limitations?
This was not a randomized trial
The number of patients was relatively small
Patients were carefully selected, so results may not apply to everyone
Bottom line
For patients with pancreatic cancer that has spread to the abdomen, surgery combined with HIPEC may offer a potential benefit for a small, carefully selected group, but more research is needed before it becomes a standard treatment.
